Comparative Pharmacology
Head-to-head clinical analysis: LONOX versus XERMELO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LONOX versus XERMELO.
LONOX vs XERMELO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Loperamide is an opioid receptor agonist that acts on mu-opioid receptors in the myenteric plexus of the large intestine, inhibiting peristalsis and prolonging transit time. It also reduces colonic water and electrolyte secretion, enhancing fluid and electrolyte absorption. Loperamide has low systemic bioavailability due to extensive first-pass metabolism and is not significantly absorbed into the central nervous system due to P-glycoprotein efflux transport.
Telotristat ethyl is a prodrug that is hydrolyzed to the active metabolite telotristat, an inhibitor of tryptophan hydroxylase (TPH). TPH is the rate-limiting enzyme in the peripheral conversion of tryptophan to serotonin. By inhibiting TPH, telotristat reduces serotonin production in the gut, thereby decreasing gastrointestinal motility and secretion, and reducing diarrhea associated with carcinoid syndrome.
1-2 mg orally every 6 hours as needed for diarrhea; maximum 8 mg per day.
250 mg orally three times daily with or without food.
None Documented
None Documented
Terminal half-life 12-15 hours; prolonged (up to 30 h) in elderly and renal impairment.
Terminal elimination half-life is approximately 6-10 hours in patients with carcinoid syndrome, supporting twice-daily dosing. In patients with moderate hepatic impairment, half-life may be prolonged to up to 19 hours.
Primarily renal (60-70% as unchanged drug and active metabolite); biliary/fecal ~20%.
Primarily excreted via feces (approximately 82% of absorbed dose) with a minor renal component (approximately 12% of absorbed dose as unchanged drug and metabolites).
Category C
Category C
Antidiarrheal
Antidiarrheal